Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Withdrawn 3Completed 3Unknown 2Terminated 1

Sponsor Class

OTHER_GOV 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gynecologic 1

Conditions

Uterine Cervical Neoplasms 1Refractory Solid Tumors 1Lung Neoplasms 1

Interventions

Cyclophosphamide 1488Cisplatin 1410Paclitaxel 1316Radiotherapy 1259Carboplatin 1247Gemcitabine 1214Docetaxel 1110Bevacizumab 1029Fluorouracil 894Doxorubicin 786Dexamethasone 746Rituximab 719Capecitabine 716Oxaliplatin 700pembrolizumab 673Etoposide 673Irinotecan 634Filgrastim 621Cytarabine 584Leucovorin 578Nivolumab 557Vincristine 510Prednisone 474Cetuximab 464Bortezomib 457Erlotinib Hydrochloride 456Trastuzumab 448Methotrexate 437Lenalidomide 426Pemetrexed 419

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Interventional × Hydralazine × Clear all
NCT00996060 2016-01-18

Use of Hydralazine and Valproic Acid in Advanced Solid Tumor Malignancies

New Mexico Cancer Research Alliance

Phase 1 Completed
29 enrolled
Thoracic

Lung Neoplasms

NCT00404326 2006-11-28

Hydralazine and Valproate Plus Cisplatin Chemoradiation in Cervical Cancer

National Institute of Cancerología

Phase 2 Completed
18 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT00404508 2006-11-28

A Phase II Study of Epigenetic Therapy to Overcome Chemotherapy Resistance in Refractory Solid Tumors

National Institute of Cancerología

Phase 2 Completed
15 enrolled
Other solid neoplasm

Refractory Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡